Decision Support in Utah

Epitel, Inc. is a digital health company based in Salt Lake City, Utah, specializing in innovative wearable EEG monitoring technology for brain health. Founded in 2008, Epitel developed the REMI™ Remote EEG Monitoring System, an FDA-cleared (2021) wireless, wearable sensor platform designed for seizure detection and electrographic monitoring in both hospital and ambulatory settings. The system features single-channel, high-fidelity EEG recordings with rapid setup (minutes), wireless operation enabling patient mobility, and integration with standard EEG review platforms like Persyst™ Mobile for remote clinician review. REMI Vigilenz™ AI for Event Detection augments clinical review by automatically identifying potential electrographic seizure activity with confidence scoring. The platform is clinically validated, reimbursable under existing codes, and suitable for adult and pediatric patients (1+ years for monitoring; 6+ years for AI analysis). Epitel's technology addresses critical care, emergency department, and outpatient epilepsy monitoring needs. The company has secured over $20 million in funding and brings extensive expertise in medical device development, neural engineering, and regulatory affairs.

ARUP Laboratories is a national, academic, nonprofit reference laboratory established in 1984 as part of the University of Utah's Department of Pathology. Operating 65 highly automated laboratory facilities with 4,300 employees, ARUP serves healthcare providers nationwide with over 3,000 diagnostic tests. The laboratory maintains a two-story freezer capable of storing 2.3 million specimens and provides industry-leading turnaround times. ARUP's test menu encompasses genetics, molecular oncology, pediatrics, neurology, hematopathology, and infectious disease testing. Beyond core laboratory services, ARUP offers comprehensive consulting through its Healthcare Advisory Services division, addressing laboratory stewardship, operations optimization, outreach planning, and data analytics. The company maintains a robust research and innovation program through its Institute for Research and Innovation in Diagnostic and Precision Medicine, supporting clinical trials, pharmaceutical companion diagnostics, and academic research initiatives. ARUP provides ARUP Consult®, a clinical decision support resource featuring testing algorithms and expert insights, alongside continuing education for laboratory professionals. CAP-, CLIA-, and ISO 15189-accredited, ARUP serves academic medical centers, children's hospitals, government facilities, and healthcare systems across the U.S.

Videra Health is an AI-powered behavioral health technology platform that automates clinical documentation, remote patient monitoring, and clinical decision support through multimodal analysis of video, audio, and text data. Founded in 2019 and based in Orem, Utah, the company serves 300+ behavioral health facilities with 1M+ patient interactions. The platform features automated patient intake, AI-generated clinical summaries (Sidekick Notes), real-time emotional and risk analysis, and 24/7 patient engagement across multiple channels (video, voice, chat, SMS). Key capabilities include suicide risk detection, tardive dyskinesia screening, and group therapy documentation. Videra's system delivers measurable operational outcomes: 2+ clinician hours reclaimed daily, 85% faster patient engagement, and 64% reduction in crisis interventions. HIPAA and SOC 2 Type II compliant, FDA-registered, and designed specifically for behavioral health workflows in value-based care models.

Myriad Genetics is a clinical laboratory and precision medicine company specializing in genetic and genomic testing for hereditary cancer risk, oncology, reproductive health, urology, and mental health. The company operates five primary service lines: (1) Hereditary Cancer Risk—germline testing to identify predisposition to 11 hereditary cancers; (2) Oncology—tumor genomic profiling and companion diagnostics for treatment selection; (3) Reproductive Health—carrier screening and prenatal genetic testing; (4) Urology—prostate cancer prognostic testing; and (5) Mental Health/Pharmacogenomics—testing to guide psychotropic medication selection. Founded over 30 years ago, Myriad maintains one of the largest ancestry-diverse genomic databases and emphasizes clinically actionable, easily interpretable reporting. The company operates CLIA-certified laboratories and serves patients and healthcare providers across the United States and internationally through multiple service centers. All major test products are designed to inform clinical decision-making at points of detection, treatment initiation, and disease prevention. Myriad maintains robust infrastructure for provider ordering, patient support, genetic counseling, and financial assistance programs.